• Bausch + Lomb reported progress on BL1243, an oral candidate for dry age-related macular degeneration, after a constructive FDA meeting clarified the initial clinical study design and broader development path.
• The move to advance tonabersat as BL1243 for early stage dry AMD targets a large retinal disease segment where existing treatment choices remain limited. This could reshape how the business allocates research spending inside its Pharma portfolio.
• We will now look at how this new oral dry AMD program might reshape Bausch + Lomb's investment narrative and perceived growth mix.

Spot 32 healthcare AI stocks that, like Bausch + Lomb, are leaning into next-generation eye and vision treatments, where early clinical progress can quickly reshape how investors view a pipeline.

Bausch + Lomb Investment Narrative Recap

For a shareholder in Bausch + Lomb, the core belief is that a focused eye health platform can turn current losses into steadier cash generation over time. The short term story still leans on prescription momentum in dry eye treatments, progress in contact lenses and premium surgical products, and cost work under the Vision 27 program.

The BL1243 update sits in the background of that near term picture. It adds depth to the retinal pipeline but does not change the main upcoming catalyst, which remains execution on Miebo, Xiidra and margin improvement. The biggest immediate risk still looks operational, including manufacturing quality issues and any drag on Pharma from regulatory findings.

The BL1243 progress is the clearest link between this news and Bausch + Lomb’s broader catalyst list. Management now has an agreed initial study design with the FDA and plans to start the dry AMD clinical program in 2027. That timetable reinforces the idea that R&D spend is being directed toward assets with defined development milestones.

For investors, this development matters most alongside products already in the market such as Miebo and Xiidra. Early clinical steps in dry AMD expand the long term Pharma opportunity, while current prescriptions and pricing remain central to funding that research and to any improvement in margins and free cash flow over the next few years.

Bausch + Lomb's current analyst storyline points to revenue of US$6.4b and earnings of US$325.4m by 2029. That profile assumes revenue expands at about 6.2% a year and earnings shift from a loss of US$171.0m today to the projected profit, an improvement of roughly US$496m.

Uncover why Bausch + Lomb's fair value indicates a 13% potential upside to its current price that could narrow quickly.

Exploring Other Perspectives

Some of the lowest Bausch + Lomb forecasts lean hard into execution risk on the Vision 27 program. Those analysts were pencilling in US$6.1b of revenue and US$237.6m of earnings by 2029, clearly below consensus. That gap shows how sharply opinions can diverge and why you may want to compare several viewpoints as this BL1243 update filters through future models.

Explore 4 other Bausch + Lomb fair value estimates, including one that suggests it could be worth just $19.39.

Reach Your Own Conclusion

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• See our latest analysis for Bausch + Lomb. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Looking for more investment ideas beyond Bausch + Lomb?

If this Bausch + Lomb update has sharpened your focus on where future cash flows might come from, it can help to line it up against other potential opportunities. The Simply Wall St Screener lets you quickly scan for different profiles, whether you care most about value, resilience, or dividend income.

• If strong cash generation at a reasonable price is your priority, start with a curated set of value opportunities through the 27 high quality undervalued stocks.
• If balance sheet strength and durability matter most to you, filter for companies with low financial risk using the list of solid balance sheet and fundamentals (25 results).
• If income is at the top of your checklist, focus on reliable payout candidates screened via the 8 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.